Search Results - "Ge, Joy"

Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine by Hewitt, David J, Aurora, Sheena K, Dodick, David W, Goadsby, Peter J, Ge, Yang Joy, Bachman, Robert, Taraborelli, Donna, Fan, Xiaoyin, Assaid, Christopher, Lines, Christopher, Ho, Tony W

“…This study evaluated the CGRP receptor antagonist MK-3207 for acute treatment of migraine. Multicenter, double-blind, randomized, placebo-controlled,…”
Get more information

Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412 by Machiels, Jean-Pascal, Tao, Yungan, Burtness, Barbara, Tahara, Makoto, Licitra, Lisa, Rischin, Danny, Waldron, John, Simon, Christian, Gregoire, Vincent, Harrington, Kevin, Alves, Gustavo Vasconcelos, Figueiredo Lima, Iane Pinto, Pointreau, Yoann, M Hughes, Brett G, Aksoy, Sercan, Hetnal, Marcin, Ge, Joy Y, Brown, Holly, Cheng, Jonathan, Bidadi, Behzad, Siu, Lillian L

“…Current treatment guidelines for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) recommend multimodal treatment, including…”
Get full text

A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine by Voss, Tiffini, Lipton, Richard B, Dodick, David W, Dupre, Nicole, Ge, Joy Yang, Bachman, Robert, Assaid, Christopher, Aurora, Sheena K, Michelson, David

“…The aim of this trial was to evaluate the efficacy and tolerability of ubrogepant (MK-1602), a calcitonin gene-related peptide receptor antagonist (CGRP-RA),…”
Get more information

Orexin Receptor Antagonism in Painful Diabetic Neuropathy: A Phase 2 Trial With Filorexant by Joseph Herring, W, Ge, Joy Y, Jackson, Saheeda, Assaid, Christopher, Connor, Kathryn M, Michelson, David

“…OBJECTIVES:To evaluate whether orexin receptor antagonism with filorexant provides pain relief in patients with painful diabetic neuropathy (PDN). METHODS:In…”
Get full text

Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629 by Bratland, Åse, Munoz-Couselo, Eva, Mortier, Laurent, Roshdy, Osama, González, Rene, Schachter, Jacob, Arance, Ana M., Grange, Florent, Meyer, Nicolas, Joshi, Abhishek Jagdish, Billan, Salem, Hughes, Brett G. M., Grob, Jean-Jacques, Ramakrishnan, Karthik, Ge, Joy, Gumuscu, Burak, Swaby, Ramona F., Gutzmer, Ralf

“…Introduction At first interim analysis of KEYNOTE-629, health-related quality of life (HRQoL) with pembrolizumab was stable or improved over 48 weeks in…”
Get full text

Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study by Cho, Byoung Chul, Braña, Irene, Cirauqui, Beatriz, Aksoy, Sercan, Couture, Felix, Hong, Ruey-Long, Miller, Jr, Wilson H, Chaves-Conde, Manuel, Teixeira, Margarida, Leopold, Lance, Munteanu, Mihaela, Ge, Joy Yang, Swaby, Ramona F, Hughes, Brett G M

“…Advanced head and neck squamous cell carcinoma (HNSCC) has a poor prognosis, and new treatment options are needed. Combining immunotherapies with differing…”
Get full text

351 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009 by Harrington, Kevin, Cohen, Ezra, Siu, Lilian, Rischin, Danny, Licitra, Lisa, Vermorken, Jan, Le, Quynh-Thu, Tahara, Makoto, Machiels, Jean-Pascal, Hawk, Natalyn, Ge, Joy, Bidadi, Behzad, Swaby, Ramona, Burtness, Barbara

“…BackgroundPembrolizumab alone and in combination with platinum-based chemotherapy have become standard first-line treatment options for recurrent/metastatic…”
Get full text

Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study by Machiels, Jean-Pascal H., Licitra, Lisa F., Tao, Yungan, Yen, Chia-Jui, Rischin, Danny, Waldron, John, Burtness, Barbara, Gregoire, Vincent, Agarwala, Sanjiv S., Yorio, Jeffrey, Delord, Jean-Pierre, Aksoy, Sercan, Ikeda, Sadakatsu, Hong, Ruey-Long, Ge, Joy Yang, Brown, Holly M., Bidadi, Behzad, Siu, Lillian L.

“…Abstract only…”
Get full text

Reply to “Keynote 48: Is it really for everyone?” by Burtness, Barbara, Ge, Joy

Get full text

Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine by Ho, Tony W, Ho, Andrew P, Ge, Yang Joy, Assaid, Christopher, Gottwald, Regina, MacGregor, E Anne, Mannix, Lisa K, van Oosterhout, Willebrordus P J, Koppenhaver, Janelle, Lines, Christopher, Ferrari, Michel D, Michelson, David

“…The aim of this article is to evaluate the safety and efficacy of perimenstrual telcagepant, a CGRP receptor antagonist, for headache prophylaxis. We conducted…”
Get more information

A Two-Stage Adaptive Design in Phase 2 Clinical Trials for Acute Treatment of Migraine by Fan, Xiaoyin Frank, Assaid, Chris A., Ge, Yang Joy, Ho, Tony W. H.

“…In the development of acute migraine treatments, traditional phase 2 dose-finding trial designs are particularly challenging when a wide dose range needs to be…”
Get full text

Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score by Burtness, Barbara, Rischin, Danny, Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro, Jr, Gilberto, Psyrri, Amanda, Brana, Irene, Basté, Neus, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G M, Mesia, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Wan Ishak, Wan Zamaniah, Ge, Joy, Swaby, Ramona F, Gumuscu, Burak, Harrington, Kevin

“…The phase III KEYNOTE-048 (ClinicalTrials.gov identifier: NCT02358031) trial of pembrolizumab in recurrent or metastatic (R/M) head and neck squamous cell…”
Get full text

Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D by Patnaik, Amita, Socinski, Mark A., Gubens, Matthew A., Gandhi, Leena, Stevenson, James, Bachman, Robert D., Bourque, Jennifer, Yang Ge, Joy, Im, Ellie, Gadgeel, Shirish M.

“…Abstract only…”
Get full text

34762 Adjuvant pembrolizumab versus placebo in high-risk locally advanced cutaneous squamous cell carcinoma: The phase 3 KEYNOTE-630 study by Schenker, Michael, Klochikhin, Mikhail, Bratland, Ase, Kirtbaya, Dmitry, Guminski, Alexander, Dzienis, Marcin, Schmults, Chrysalyne, Ge, Joy Y., Yuan, Jianda, Lee, Jenny

Get full text

Abstract LB-138: Adjuvant pembrolizumab or placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma: Phase 3 KEYNOTE-630 by Chang, Anne Lynne S., Daniels, Gregory A., Cohen, Ezra E., Ge, Joy Yang, Gumuscu, Burak, Swaby, Ramona F., Geiger, Jessica L.

“…Background: Local recurrence occurs within 5 years in ~20% of patients with high-risk locally advanced cutaneous squamous cell carcinoma treated with current…”
Get full text

KEYNOTE-630: Phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma by Geiger, Jessica Lyn, Daniels, Gregory A., Cohen, Ezra E.W., Ge, Joy Yang, Gumuscu, Burak, Swaby, Ramona F., Chang, Anne Lynn S.

“…Abstract only TPS9597 Background: Among patients with high-risk, locally advanced (LA) cutaneous squamous cell carcinoma (cSCC) who receive current…”
Get full text

Abstract CT285: KEYNOTE-689: A phase 3 study of neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) by Lee, Nancy Y., Uppaluri, Ravindra, Westra, William, Cohen, Ezra E., Haddad, Robert I., Temam, Stephane, Le Tourneau, Christophe, Chernock, Rebecca, Safina, Sufia, Klochikhin, Arkadiy, Meirovitz, Amichay, Brana, Irene, Ge, Joy Yang, Swaby, Ramona F., Pinheiro, Cecilia, Adkins, Douglas

“…Background: In phase 2 studies (NCT02296684 and NCT02641093), neoadjuvant and adjuvant pembrolizumab demonstrated a pathological response (PR) and acceptable…”
Get full text

P-94 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009 by Harrington, Kevin J., Cohen, Ezra E.W., Siu, Lillian, Rischin, Danny, Licitra, Lisa, Vermorken, Jan, Le, Quynh, Tahara, Makoto, Machiels, Jean-Pascal, Hawk, Natalyn, Ge, Joy, Bidadi, Behzad, Swaby, Ramona F., Burtness, Barbara

Get full text

A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669 by Cohen, Ezra E.W., Rischin, Danny, Pfister, David G., Vermorken, Jan Baptist, Zhao, Yufan, Gowda, Hema, Ge, Joy Yang, Jin, Fan, Harrington, Kevin J.

“…Abstract only…”
Get full text

KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma by Uppaluri, Ravindra, Lee, Nancy Y., Westra, William, Cohen, Ezra E.W., Haddad, Robert I., Temam, Stephane, Le Tourneau, Christophe, Chernock, Rebecca, Safina, Sufia, Klochikhin, Arkadiy, Meirovitz, Amichay, Braña, Irene, Ge, Joy Yang, Swaby, Ramona F., Bidadi, Behzad, Adkins, Douglas

“…Abstract only TPS6090 Background: Evidence of efficacy and pathological response at the time of surgery was reported in two phase 2 studies (NCT02296684 and…”
Get full text